Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.

Launched by THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY · Aug 2, 2021

Keywords

ClinConnect Summary

This is a multi-center, randomized, open-label, controlled pilot study of Traditional Chinese medicine (Qing-Re-Liang-Xue Decoction) as a complementary therapy to treat psoriasis vulgaris of blood-heat syndrome during a 10-week period. We estimate to enroll 200 subjects (treatment group(N=100); controlled group(N=100)).

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18-65 years;
• • Had a diagnosis of psoriasis vulgaris for ≥6 months;
• • TCM syndrome evaluation belongs to blood-heat type patients: it is more common in the advanced stage of psoriasis. Symptoms: skin lesions develop faster, skin lesions are bright red, blood loss is obvious, scales are dry and thick, itching is severe; upset, and thirsty, dry stool; red-purple tongue, yellow fur, string or slippery or rapid pulse;
• • Patients without serious primary diseases, such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system or mental illnesses;
• • Those who are willing to cooperate and can persist in the treatment without interruption;
• • During the treatment period, those who have not taken or used other psoriasis drugs externally.
• Exclusion Criteria:
• • Patients with serious primary diseases, such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system or mental illnesses;
• • History of immunosuppressant medication in the past three months;
• • Those who use other drugs during treatment or stop treatment on their own and have incomplete observation data;
• • Pregnancy or risk of pregnancy, and/or lactation;
• • Aged ≤18 or ≥65 years old;
• • Patients with other types of psoriasis, such as articular, pustular, and erythroderma.